In 2019, PRL-3-zumab, a First-in-Class humanized antibody drug, demonstrated the ability to bind to the surface of PRL-3 in a manner consistent with the classical antibody-dependent cell-mediated cytotoxicity (ADCC) action or antibody-dependent cell phagocytic tumor elimination pathway [140,156]. Here, PTP4A3 is linked to neoplasm.